Investors Must Face Reality: Global Blood Therapeutics Inc. (GBT)

Global Blood Therapeutics Inc.’s stock (NASDAQ:GBT) has been rated as Overweight by Cantor Fitzgerald. This latest rating was contained in a recent research note...

A Bet That Definitely Worked; But Persistence Needed: Iovance Biotherapeutics Inc. (IOVA)

Iovance Biotherapeutics Inc.’s stock (NASDAQ:IOVA) has been rated as Mkt Outperform by JMP Securities. This latest rating was contained in a recent research note...

Hocus Pocus, But Be Focus on Workhorse Group Inc. (WKHS)

Workhorse Group Inc.’s stock (NASDAQ:WKHS) has been rated as Buy by Maxim Group. This latest rating was contained in a recent research note published...

Still Better Pick Than Rivals: Spectrum Pharmaceuticals Inc. (SPPI)

Spectrum Pharmaceuticals Inc.’s stock (NASDAQ:SPPI) has been rated as Neutral by Guggenheim. This latest rating was contained in a recent research note published by...

Short-Range And Lasting Prospect: Amicus Therapeutics Inc. (FOLD)

Amicus Therapeutics Inc.’s stock (NASDAQ:FOLD) has been rated as Buy by H.C. Wainwright. This latest rating was contained in a recent research note published...

Searching For A True Swing in Pinterest Inc. (PINS)? Read This

Pinterest Inc.’s stock (NYSE:PINS) has been rated as Overweight by Wells Fargo. This latest rating was contained in a recent research note published by...

Positive Sentiments For Turnaround Ahead: BioCryst Pharmaceuticals Inc. (BCRX)

BioCryst Pharmaceuticals Inc.’s stock (NASDAQ:BCRX) has been rated as Buy by BofA/Merrill. This latest rating was contained in a recent research note published by...

Analyzing the Sprouts Farmers Market Inc. (SFM) Using Returns

Sprouts Farmers Market Inc.’s stock (NASDAQ:SFM) has been rated as Underweight by Wells Fargo. This latest rating was contained in a recent research note...

The Risk-Free Opportunity For Individual Investors: Superconductor Technologies Inc. (SCON)

Superconductor Technologies Inc.’s stock (NASDAQ:SCON) has been rated as Buy by Rodman & Renshaw. This latest rating was contained in a recent research note...

A Better Value Now Despite Modest Revenue Growth: 22nd Century Group Inc. (XXII)

22nd Century Group Inc.’s stock (NYSE:XXII) has been rated as Buy by Chardan Capital Markets. This latest rating was contained in a recent research...